Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.

@article{Taylor2011RapidDO,
  title={Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.},
  author={Barbara Sieck Taylor and Gillian Hunt and Elaine J. Abrams and Ashraf H. Coovadia and Tammy Meyers and Gayle Sherman and Renate Strehlau and Lynn Morris and Louise Kuhn},
  journal={AIDS research and human retroviruses},
  year={2011},
  volume={27 9},
  pages={945-56}
}
Data on the development of antiretroviral drug resistance in HIV-1-infected children receiving protease inhibitor (PI)-based antiretroviral therapy (ART) are limited. We examined antiretroviral resistance among a cohort of 323 South African HIV-infected children <2 years old exposed to nevirapine for prevention of mother-to-child transmission. Ritonavir (RTV) was used initially for 138 children who were <6 months old or receiving antimycobacterial therapy; otherwise children received lopinavir… CONTINUE READING